# 🎯 Blood Pressure Targets

## 🎯 Key Target Principles

1 **General Population:** \<130/80 mmHg for most patients when tolerated 2 **High-Risk Groups:** \<130/80 mmHg mandatory (CVD, DM, CKD with albuminuria) 3 **Intensive Targets:** \<120 mmHg systolic when appropriate and tolerated 4 **Individualization:** Consider age, frailty, comorbidities, and patient preferences

## 📊 Cardiovascular Risk Reduction by BP Level

| Per 10 mmHg SBP Reduction | Outcome | Relative Risk Reduction | Hazard Ratio | Source |
|----|----|----|----|----|
| **10 mmHg ↓ SBP** | Major CV events (composite) | 20% | HR 0.80 (95% CI 0.77-0.83) | Ettehad 2016 [PMID 26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/) |
|  | Coronary heart disease | 17% | HR 0.83 (95% CI 0.78-0.88) | Ettehad 2016 |
|  | Stroke | 27% | HR 0.73 (95% CI 0.68-0.77) | Ettehad 2016 |
|  | Heart failure | 28% | HR 0.72 (95% CI 0.67-0.78) | Ettehad 2016 |
| **BPLTTC 2021 (Rahimi et al., *Lancet* 397:1625-1636, [PMID 33933205](https://pubmed.ncbi.nlm.nih.gov/33933205/))** — individual-patient meta-analysis (n=344,716, 48 trials): per 5 mmHg SBP reduction, major CV event HR 0.91 (95% CI 0.89-0.94) in primary prevention and 0.89 (0.86-0.92) in secondary prevention — approximately 10% RRR per 5 mmHg, with relative effect **consistent across baseline SBP strata** from \<120 to ≥170 mmHg. Companion age-stratified analysis (Lancet 2021;398:1053-1064, [PMID 34461040](https://pubmed.ncbi.nlm.nih.gov/34461040/)) extended this finding to age groups: HR 0.82 (\<55y), 0.91 (55-84y), 0.99 (≥85y). Together these confirm the constant-RRR pattern of Ettehad 2016 across baseline BP, baseline CV history, and age (with attenuation only in the ≥85y subgroup). |  |  |  |  |

Implication for absolute risk: a patient with starting SBP 180 and 10-year CV risk 30% gets larger absolute benefit from 10 mmHg reduction (ARR approximately 6 percentage points per decade) than a patient with starting SBP 140 and 10-year CV risk 5% (ARR approximately 1 percentage point per decade) — even though RRR is the same approximately 20%. The "diminishing returns" pedagogy is correct at the absolute-benefit level but does not reflect a true falloff in relative effect. Tailor target-intensity decisions to baseline absolute risk, not relative effect estimates.

## 🔬 Major Trial Evidence

### 💪 SPRINT Trial - Intensive vs Standard

- **Population:** High-risk non-diabetic patients (N=9,361)
- **Targets:** \<120 mmHg vs \<140 mmHg systolic
- **Primary Outcome:** 25% relative risk reduction
- **Absolute Benefit:** 1.6% over 3.26 years (2.5% over 5 years)
- **NNT:** 61 to prevent one primary outcome event
- **Mortality Benefit:** 27% relative reduction, 1.2% absolute

### 👴 STEP Trial - Elderly Patients

- **Population:** Chinese adults age 60-80 years (N=8,511)
- **Targets:** SBP 110-130 mmHg vs 130-150 mmHg
- **Primary Outcome:** HR 0.74 (26% relative risk reduction)
- **Absolute Benefit:** ARR approximately 1.1% over 3.34 years (event rate 3.5% intensive vs 4.6% standard); NNT 91
- **Key Finding:** Confirmed benefit of intensive BP control extends to elderly Chinese population
- **Source:** Zhang W et al. *NEJM* 2021;385(14):1268-1279, PMID 34491661
- 

### 🧠 SPRINT-MIND - Cognitive Outcomes

- **Cognitive Focus:** Mild cognitive impairment prevention
- **Result:** 19% reduction in mild cognitive impairment
- **Brain Health:** Intensive BP control preserves cognition
- **Dementia:** Trend toward reduced dementia risk
- **Implications:** Brain protection beyond cardiovascular benefits
- **Age Consideration:** Midlife hypertension particularly harmful

## ⚖️ Intensive Targets: Benefits vs Risks

### ✅ Benefits of \<120 mmHg Target

**SPRINT Trial as published (3.26-year follow-up; SPRINT primary paper Wright NEJM 2015, PMID 26551272)**

- **All-cause mortality:** HR 0.73, ARR 1.2% (NNT 83)
- **Primary CV composite:** HR 0.75, ARR 1.6% (NNT 61)
- **Heart failure:** HR 0.62 (38% RRR)
- **Cognitive protection (SPRINT-MIND):** HR 0.81 for MCI (19% RRR)
- **Renal outcomes:** Slower eGFR decline in non-CKD subset; mixed in baseline CKD
- 

### ⚠️ Risks of \<120 mmHg Target

**SPRINT Trial Adverse Events as published (3.26-year follow-up)**

- **Hypotension/syncope/AKI/electrolyte SAEs:** HR approximately 1.33–1.67 in intensive arm (statistically significant)
- **Falls with injury:** HR 1.00 — NO increase, including in SPRINT-Senior subgroup ≥75y
- **Acceptable safety profile** for the absolute risk magnitudes given the cardiovascular benefit
- 

## 👥 Population-Specific Target Recommendations

### 🌟 High-Risk Patients

**Target: \<130/80 mmHg (Class 1 Recommendation)**

- **Established CVD:** CAD, stroke, PAD, heart failure
- **Diabetes Mellitus:** Type 1 or 2 with any complications
- **CKD with Albuminuria:** ≥30 mg/g albumin/creatinine ratio
- **10-Year CVD Risk ≥10%:** Based on PREVENT calculator
- **Evidence:** Consistent benefit across multiple trials
- **Monitoring:** More frequent follow-up required

### 👴 Elderly Patients (\>80 years)

**Target: Individualized, Often 140-150 mmHg Systolic**

- **Frailty Assessment:** Consider functional status and life expectancy
- **Comorbidity Burden:** Multiple conditions may limit benefit
- **Fall Risk:** Orthostatic hypotension prevention priority
- **Cognitive Function:** Severe dementia may preclude intensive targets
- **Goals of Care:** Quality of life vs longevity considerations
- **Gradual Approach:** Slow titration to avoid complications

### 🫀 Special Cardiac Conditions

**Target: Condition-Specific Considerations**

- **CAD with Wide PP:** Avoid diastolic \<70 mmHg
- **Heart Failure:** \<130/80 mmHg if tolerated
- **Aortic Stenosis:** Careful reduction to maintain perfusion
- **Hypertrophic Cardiomyopathy:** Avoid excessive reduction
- **Post-MI:** \<130/80 mmHg for secondary prevention
- **Atrial Fibrillation:** Consider stroke risk in target selection

### 🫘 Chronic Kidney Disease

**Target: \<130/80 mmHg Across All CKD Stages**

- **Unified Approach:** Same target regardless of CKD stage
- **Albuminuria:** RAAS inhibition mandatory if present
- **eGFR Monitoring:** 30% increase acceptable with RAAS inhibitors
- **Progression Prevention:** BP control slows CKD advancement
- **CVD Protection:** Reduced cardiovascular events
- **Dialysis Patients:** Individualized based on fluid status

## 🌡️ Diastolic Blood Pressure Considerations

### 📈 Age-Related Changes

- **Young Adults (\<50):** Diastolic BP equally important predictor
- **Middle Age (50-59):** Systolic becomes predominant
- **Elderly (≥60):** Only systolic BP remains significant predictor
- **Mechanism:** Arterial stiffening with aging
- **Pulse Pressure:** Widens progressively with age
- **Clinical Focus:** Shift emphasis to systolic in elderly

### ⚠️ Wide Pulse Pressure Risks

- **Definition:** Pulse pressure ≥60 mmHg (some use ≥70 mmHg)
- **Prevalence:** 42% in patients ≥65 years with hypertension
- **J-Curve Risk:** Diastolic \<70 mmHg with CAD increases events
- **Coronary Perfusion:** Occurs primarily during diastole
- **High-Risk Groups:** CAD, diabetes, age \>75 years
- **Management:** Target systolic while avoiding low diastolic

### 🧮 Blood Pressure Target Calculator

Determine appropriate BP target based on patient characteristics

Patient Age: Established cardiovascular disease: Diabetes mellitus: CKD with albuminuria: Frailty status (if elderly): Coronary artery disease with wide pulse pressure: Target recommendation will appear here

## 🎯 Practical Implementation Strategies

### 📈 Stepwise Approach to Target Achievement

- **Initial Goal:** \<140/90 mmHg for all patients
- **Secondary Goal:** \<130/80 mmHg if tolerated
- **Intensive Goal:** \<120 mmHg systolic in selected patients
- **Monitoring Frequency:** Every 2-4 weeks during titration
- **Medication Adjustment:** Add/increase every 2-4 weeks
- **Plateau Phase:** Monthly monitoring once stable

### 🏥 Clinical Monitoring Guidelines

- **Home BP Monitoring:** Essential for accurate assessment
- **Laboratory Monitoring:** Electrolytes, creatinine every 2-4 weeks
- **Symptom Assessment:** Dizziness, fatigue, syncope
- **Adherence Evaluation:** Pill counts, pharmacy records
- **Lifestyle Reinforcement:** Diet, exercise, weight management
- **Complication Screening:** Target organ damage assessment

## 🚫 When to Avoid Intensive Targets

### ⚠️ Absolute Contraindications

- **Symptomatic Hypotension:** Dizziness, falls, syncope
- **Severe Orthostatic Hypotension:** \>20/10 mmHg drop
- **Limited Life Expectancy:** \<2-3 years prognosis
- **Severe Frailty:** High fall risk, cognitive impairment
- **Medication Intolerance:** Multiple drug allergies/intolerances
- **Patient Preference:** Informed refusal of intensive therapy

### 🤔 Relative Contraindications

- **Advanced Age:** \>85 years without clear benefit
- **Multiple Comorbidities:** Complex medical conditions
- **Polypharmacy:** \>10 medications with interaction risk
- **Cognitive Impairment:** Moderate-severe dementia
- **Recent Stroke:** Within 3 months, individualize
- **Social Factors:** Poor follow-up, medication access issues

## 📋 Evidence-Based Target Selection Algorithm

### 🎯 Systematic Approach to BP Target Selection

1 **Risk Assessment:** Evaluate CVD risk, comorbidities, and life expectancy 2 **Initial Target:** \<140/90 mmHg for all patients as starting goal 3 **High-Risk Evaluation:** Consider \<130/80 mmHg for CVD, DM, CKD 4 **Intensive Consideration:** \<120 mmHg systolic if high risk and tolerated 5 **Individualization:** Adjust based on tolerance, frailty, and preferences 6 **Monitoring:** Regular assessment for benefits and adverse effects

## 📚 Sources

1.  **Ettehad D, Emdin CA, Kiran A, et al.** Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-967. [PMID: 26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/). \[Source for: per-10-mmHg constant RRR — major CV events HR 0.80, CHD HR 0.83, stroke HR 0.73, heart failure HR 0.72; n=613,815, 123 trials.\]
2.  **Rahimi K, et al; Blood Pressure Lowering Treatment Trialists' Collaboration.** Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet.* 2021;397(10285):1625-1636. [PMID: 33933205](https://pubmed.ncbi.nlm.nih.gov/33933205/). \[Source for: constant-RRR finding across baseline SBP strata; primary vs secondary prevention HR 0.91 vs 0.89 per 5 mmHg; n=344,716, 48 trials.\]
3.  **Rahimi K, et al; Blood Pressure Lowering Treatment Trialists' Collaboration.** Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. *Lancet.* 2021;398(10305):1053-1064. [PMID: 34461040](https://pubmed.ncbi.nlm.nih.gov/34461040/). \[Source for: age-stratified effects — HR 0.82 (\<55y) to 0.99 (≥85y); n=358,707, 51 trials.\]
4.  **SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al.** A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med.* 2015;373(22):2103-2116. [PMID: 26551272](https://pubmed.ncbi.nlm.nih.gov/26551272/). \[Source for: SPRINT primary outcome HR 0.75 (25% RRR), all-cause mortality HR 0.73 (27% RRR), heart failure HR 0.62, NNT 61 over 3.26 years; N=9,361.\]
5.  **Zhang W, Zhang S, Deng Y, et al.** Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP). *N Engl J Med.* 2021;385(14):1268-1279. [PMID: 34491661](https://pubmed.ncbi.nlm.nih.gov/34491661/). \[Source for: STEP primary composite HR 0.74 (26% RRR); event rate 3.5% intensive vs 4.6% standard over 3.34 years → ARR approximately 1.1%, NNT approximately 91; N=8,511 Chinese adults age 60-80.\]
6.  **Williamson JD, Pajewski NM, Auchus AP, et al; SPRINT MIND Investigators.** Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: SPRINT MIND. *JAMA.* 2019;321(6):553-561. [PMID: 30688979](https://pubmed.ncbi.nlm.nih.gov/30688979/). \[Source for: SPRINT-MIND mild cognitive impairment HR 0.81 (19% RRR); dementia trend non-significant.\]
7.  **Whelton PK, Carey RM, Aronow WS, et al.** 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Hypertension.* 2018;71(6):e13-e115. [PMID: 29133356](https://pubmed.ncbi.nlm.nih.gov/29133356/). \[Source for: Class 1 \<130/80 target for high-risk patients, intensive \<120 target indications.\]
8.  **Cameron NA, Jones DW, Khan SS, Lloyd-Jones DM.** Case-Based Applications of the 2025 AHA/ACC/Multispecialty High Blood Pressure Guideline. *Hypertension.* 2025;82(12):2055-2063. [PMID: 41204807](https://pubmed.ncbi.nlm.nih.gov/41204807/). \[Source for: 2025 AHA/ACC update reaffirms targets and risk-based approach; PREVENT calculator replaces pooled cohort equations.\]

## 🎯 Key Learning Points

**📊 Diminishing Returns:** Absolute benefit decreases as BP targets become more intensive (NNT increases) **🌟 High-Risk Priority:** \<130/80 mmHg essential for CVD, diabetes, CKD with albuminuria **👴 Age Considerations:** Individualize targets in elderly - avoid harm from overtreatment **⚠️ Wide Pulse Pressure:** Avoid diastolic \<70 mmHg in CAD patients despite elevated systolic


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/blood-pressure-targets.html) · Markdown synchronized October 3, 2026.